Document Detail


Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects.
MedLine Citation:
PMID:  6638039     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Long-term therapy with oral labetalol, an alpha- and beta-blocking agent, has been shown to effectively lower blood pressure and heart rate without decreasing cardiac output. We examined the hemodynamic effects of the acute intravenous administration of labetalol in nine hypertensive patients. Labetalol (0.6 +/- 0.1 mg/kg) promptly reduced arterial pressure, heart rate, and systemic vascular resistance without change in stroke volume. Heart rate responses to passive tilt and the Valsalva maneuver were significantly blunted. With isometric exercise, heart rate and mean arterial pressure increased significantly during labetalol therapy but less than in the pre-labetalol phase. In eight patients oral labetalol therapy was continued for six weeks (mean dose 1,050 +/- 105 mg/day), and hemodynamic evaluation was repeated. During oral labetalol therapy, decreases in arterial pressure and heart rate were sustained. Systemic vascular resistance was reduced in five of the eight patients. Hemodynamic responses to tilt, Valsalva maneuver, and handgrip were similar to those during intravenous administration. Coronary blood flow decreased, but coronary as well as pulmonary vascular resistances were unchanged. These data show the efficacy of intravenously administered labetalol in lowering blood pressure and systemic vascular resistance promptly. With long-term oral therapy, decreases in blood pressure are sustained. Labetalol does not appear to have significant effects on pulmonary or coronary vascular resistances.
Authors:
J Mehta; R L Feldman; J D Marx; G A Kelly
Related Documents :
12879109 - Oral phentolamine (vasomax).
540429 - Catecholamines and haemodynamics in fixed essential hypertension.
22885649 - Neurally adjusted ventilatory assist (nava) improves patient-ventilator interaction dur...
24919719 - Nutritional interventions for preventing and treating pressure ulcers.
6638039 - Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subj...
2896599 - Effects of cardioselective beta blockade on the peripheral lung in guinea pigs.
17138639 - Difference in plantar pressure between the preferred and non-preferred feet in four soc...
22710649 - Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than o...
7302119 - The treatment of idiopathic orthostatic hypotension: a combined fludrocortisone and flu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The American journal of medicine     Volume:  75     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  1983 Oct 
Date Detail:
Created Date:  1983-12-17     Completed Date:  1983-12-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  32-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Blood Pressure
Cardiac Output
Ethanolamines / therapeutic use*
Heart Rate
Hemodynamics*
Humans
Hypertension / drug therapy,  physiopathology*
Labetalol / administration & dosage,  therapeutic use*
Male
Middle Aged
Posture
Valsalva Maneuver
Vascular Resistance
Grant Support
ID/Acronym/Agency:
1 KOH-HL00741/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Ethanolamines; 36894-69-6/Labetalol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.
Next Document:  Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis.